Abcam, ab313629, Anti-TRIP12/ULF antibody [EPR27062-86] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal TRIP12/ULF antibody. Carrier free. Suitable for IHC-P, Flow Cyt (Intra), WB, ICC/IF and reacts with Human, Mouse, Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR27062-86,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human, Mouse, Rat,
Applications:IHC-P, ICC/IF, Flow Cyt (Intra), WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TRIP12 also known as Thyroid Hormone Receptor Interactor 12 or ULF (Ubiquitin Ligase for FBW7) is an E3 ubiquitin ligase. Mechanically TRIP12 facilitates the ubiquitination and subsequent proteasomal degradation of specific proteins. It has an approximate mass of 220 kDa. This protein is expressed in various tissues including the brain and liver. TRIP12 often interacts with other proteins through its ARM and HECT domains playing an important role in regulating protein stability.
Biological function summary
TRIP12 functions as a regulator of protein turnover impacting processes such as cell cycle progression and DNA damage responses. It is not part of a larger complex but operates independently to exert its influence. The target specifically targets proteins like p53 and FBW7 for degradation allowing cells to maintain homeostasis and adapt to changing conditions. This regulation ensures cells respond appropriately to DNA damage by either promoting repair pathways or facilitating apoptosis when repair is not feasible.
Pathways
TRIP12 plays a role in the ubiquitin-proteasome system and the p53 signaling pathway. In the ubiquitin-proteasome system TRIP12 works alongside other E3 ligases to regulate protein degradation ensuring proteins that are damaged or no longer needed are efficiently removed. Within the p53 signaling pathway TRIP12 influences the stability and activity of the tumor suppressor protein p53 helping control cell cycle arrest and apoptosis. TRIP12's relationship with FBW7 further connects it to pathways involved in cancer as FBW7 targets many oncoproteins.
TRIP12 has links to cancer and neurodevelopmental disorders. Alterations in the activity or expression of TRIP12 can lead to the accumulation of proteins like p53 which may contribute to tumorigenesis. Mutations in TRIP12 have also been associated with neurodevelopmental disorders where disrupted protein turnover impacts neural development. Its interaction with proteins such as p53 and FBW7 highlights its potential role in disease mechanisms making it a target of interest for therapeutic intervention.